Table 1.
Correlation between GSN expression and tumor progression in all patients (n = 102), early-stage and late-stage subgroups
| GSN expression | ||||
| Characteristics: All patients | Total | No. (%) | Yes (%) | P value |
| Age (years) | 0.362 | |||
| ≤55 | 56 | 15 (26.8) | 41 (73.2) | |
| >55 | 46 | 10 (21.7) | 36 (78.2) | |
| FIGO stage | 0.465 | |||
| Early stage (I plus II) | 18 | 5 (27.8) | 13 (72.2) | |
| Late stage (III plus IV) | 84 | 20 (23.8) | 64 (76.2) | |
| Differentiation | 0.367 | |||
| Poor | 54 | 12 (22.2) | 42 (77.8) | |
| Well and moderate | 48 | 13 (27.1) | 35 (72.9) | |
| Tumor progression | 0.008** | |||
| No | 31 | 13 (41.9) | 18 (58.1) | |
| Yes | 71 | 12 (16.9) | 59 (83.1) | |
| Progression-free interval | 0.138 | |||
| >6 mo | 62 | 18 (29.0) | 44 (71.0) | |
| ≤6 mo | 40 | 7 (17.5) | 33 (82.5) | |
| Tumor-progression site | 0.012* | |||
| Extrapelvis | 46 | 11 (23.9) | 35 (76.1) | |
| Pelvis | 18 | 1 (7.6) | 17 (94.4) | |
| Others | 7 | 0 (0.0) | 7 (100.0) | |
| Vital status | 0.001** | |||
| Alive | 51 | 18 (35.3) | 33 (64.7) | |
| Death | 51 | 7 (13.7) | 44 (86.3) | |
| Early-stage tumor progression | 0.5 | |||
| No | 9 | 3 (33.3) | 6 (66.7) | |
| Yes | 9 | 2 (22.2) | 7 (77.8) | |
| Early-stage progression-free interval | 0.172 | |||
| >6 mo | 15 | 3 (20.0) | 12 (80.0) | |
| ≤6 mo | 3 | 2 (66.7) | 1 (33.3) | |
| Late-stage tumor progression | 0.008** | |||
| No | 22 | 10 (45.5) | 12 (54.5) | |
| Yes | 62 | 10 (16.1) | 52 (83.9) | |
| Late-stage progression-free interval | 0.042* | |||
| >6 mo | 47 | 15 (31.9) | 32 (68.1) | |
| ≤6 mo | 37 | 5 (13.5) | 32 (86.5) | |
Data are given as n (%). Data were analyzed by χ2 test and Fisher’s exact method. *P < 0.05, **P < 0.01.